Hyperglycemia and endothelial dysfunction in atherosclerosis: Lessons from type 1 diabetes

International Journal of Vascular Medicine

Volumn 2012, Issue , 2012, Pages

  Funk, Steven Daniel ^a   Yurdagul, Arif ^a   Orr, A Wayne ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALAGEBRIUM; ALDEHYDE REDUCTASE; ALPHA TOCOPHEROL; APOLIPOPROTEIN E; BIS INDOYLMALEIMIDE 1; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EPALRESTAT; GLICLAZIDE; GLUTAMINE FRUCTOSE 6 PHOSPHATE AMINOTRANSFERASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDAPAMIDE PLUS PERINDOPRIL; INTERCELLULAR ADHESION MOLECULE 1; PF 4494700; PLACEBO; PROTEIN KINASE C; PROTEIN KINASE C BETA; PROTEIN KINASE C INHIBITOR; PYRIDOXAMINE; RAMIPRIL; RANIRESTAT; REACTIVE OXYGEN METABOLITE; RUBOXISTAURIN; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE N ACETYLGLUCOSAMINE; VASCULAR CELL ADHESION MOLECULE 1;

ACYLATION; ATHEROSCLEROSIS; CELL ACTIVATION; DIABETES MELLITUS; DIABETIC NEPHROPATHY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; METABOLISM; NONHUMAN; PROTEIN EXPRESSION; REVIEW;

EID: 84866239730     PISSN: 20902824     EISSN: 20902832     Source Type: Journal    
DOI: 10.1155/2012/569654     Document Type: Review

References (273)

1. Klingenberg R., Hansson G. K., Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. European Heart Journal 2009 30 23 2838 2844 2-s2.0-71549121695 10.1093/eurheartj/ehp477
2. Roger V. L., Go A. S., Lloyd-Jones D. M., Adams R. J., Berry J. D., Brown T. M., Carnethon M. R., Dai S., de Simone G., Ford E. S., Fox C. S., Fullerton H. J., Gillespie C., Greenlund K. J., Hailpern S. M., Heit J. A., Ho P. M., Howard V. J., Kissela B. M., Kittner S. J., Lackland D. T., Lichtman J. H., Lisabeth L. D., Makuc D. M., Marcus G. M., Marelli A., Matchar D. B., McDermott M. M., Meigs J. B., Moy C. S., Mozaffarian D., Mussolino M. E., Nichol G., Paynter N. P., Rosamond W. D., Sorlie P. D., Stafford R. S., Turan T. N., Turner M. B., Wong N. D., Wylie-Rosett J., Heart disease and stroke statistics-2011 update: a report from the American heart association. Circulation 2010 123 4 e18 e209 2-s2.0-78650046021 10.1161/CIR.0b013e3182009701
3. Collins R., Armitage J., Parish S., Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. The Lancet 2004 363 9411 757 767 10.1136/ebn.7.3.82
4. Thavendiranathan P., Bagai A., Brookhart M. A., Choudhry N. K., Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Archives of Internal Medicine 2006 166 21 2307 2313 2-s2.0-33751507008 10.1001/archinte.166.21.2307 (Pubitemid 44833354)
5. Ray K. K., Seshasai S. R. K., Erqou S., Sever P., Jukema J. W., Ford I., Sattar N., Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Archives of Internal Medicine 2010 170 12 1024 1031 2-s2.0-77954179995 10.1001/archinternmed.2010.182
6. Yusuf S., Reddy S., Ôunpuu S., Anand S., Global burden of cardiovascular diseases. Part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001 104 22 2746 2753 2-s2.0-0035960630 (Pubitemid 33108145)
7. Gortmaker S. L., Swinburn B. A., Levy D., Carter R., Mabry P. L., Finegood D. T., Huang T., Marsh T., Moodie M. L., Changing the future of obesity: science, policy, and action. The Lancet 2011 378 9793 838 847 10.1016/S0140-6736(11)60815-5
8. Ross R., Atherosclerosisan inflammatory disease. New England Journal of Medicine 1999 340 2 115 126 2-s2.0-0033552883 10.1056/NEJM199901143400207 (Pubitemid 29054847)
9. Libby P., Ridker P. M., Hansson G. K., Progress and challenges in translating the biology of atherosclerosis. Nature 2011 473 7347 317 325 10.1038/nature10146
10. Libby P., Ridker P. M., Hansson G. K., Inflammation in atherosclerosis. From pathophysiology to practice. Journal of the American College of Cardiology 2009 54 23 2129 2138 2-s2.0-70450189795 10.1016/j.jacc.2009.09.009
11. Daugherty A., Lu H., Howatt D. A., Rateri D. L., Modes of defining atherosclerosis in mouse models: relative merits and evolving standards. Methods in Molecular Biology 2009 573 1 15 2-s2.0-73949111725
12. Gimbrone M. A. Jr, Topper J. N., Nagel T., Anderson K. R., Garcia-Cardeña G., Endothelial dysfunction, hemodynamic forces, and atherogenesis. Annals of the New York Academy of Sciences 2000 902 230 240 2-s2.0-0034085698 (Pubitemid 30389128)
13. Hahn C., Schwartz M. A., Mechanotransduction in vascular physiology and atherogenesis. Nature Reviews Molecular Cell Biology 2009 10 1 53 62 2-s2.0-58049213928 10.1038/nrm2596
14. Kornerup K., Nordestgaard B. G., Jensen T. K., Feldt-Rasmussen B., Eiberg J. P., Jensen K. S., Jensen J. S., Transendothelial exchange of low-density lipoprotein is unaffected by the presence of severe atherosclerosis. Cardiovascular Research 2004 64 2 337 345 2-s2.0-5444269241 10.1016/j.cardiores. 2004.06.025 (Pubitemid 39361696)
15. Tannock L. R., King V. L., Proteoglycan mediated lipoprotein retention: a mechanism of diabetic atherosclerosis. Reviews in Endocrine and Metabolic Disorders 2008 9 4 289 300 2-s2.0-54949159199 10.1007/s11154-008-9078-0
16. Mazière C., Mazière J. C., Activation of transcription factors and gene expression by oxidized low-density lipoprotein. Free Radical Biology and Medicine 2009 46 2 127 137 2-s2.0-58049095209 10.1016/j. freeradbiomed.2008.10.024
17. Falk E., Fernandez-Ortiz A., Role of thrombosis in atherosclerosis and its complications. American Journal of Cardiology 1995 75 6 3B 11B 2-s2.0-0028910696
18. Libby P., The molecular mechanisms of the thrombotic complications of atherosclerosis. Journal of Internal Medicine 2008 263 5 517 527 2-s2.0-42149099498 10.1111/j.1365-2796.2008.01965.x (Pubitemid 351533560)
19. Libby P., Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis. Journal of lipid research 2009 263 supplement 5 S352 S357 2-s2.0-66349137052 10.1194/jlr.R800099-JLR200
20. Henschen F., On the term diabetes in the works of Aretaeus and Galen. Medical History 1969 13 2 190 192 2-s2.0-0014498393
21. Wild S., Roglic G., Green A., Sicree R., King H., Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004 27 5 1047 1053 2-s2.0-2342466734 10.2337/diacare.27.5.1047 (Pubitemid 38579764)
22. Little R. R., Sacks D. B., HbA1c: how do we measure it and what does it mean? Current Opinion in Endocrinology, Diabetes and Obesity 2009 16 2 113 118 2-s2.0-66149108471 10.1097/MED.0b013e328327728d
23. Ding H., Triggle C. R., Endothelial cell dysfunction and the vascular complications associated with type 2 diabetes: assessing the health of the endothelium. Vascular Health and Risk Management 2005 1 1 55 71 2-s2.0-21644435395 10.2147/vhrm.1.1.55.58939
24. Winer N., Sowers J. R., Epidemiology of diabetes. Journal of Clinical Pharmacology 2004 44 4 397 405 2-s2.0-1642344350 10.1177/0091270004263017 (Pubitemid 38396785)
25. Whiteley L., Padmanabhan S., Hole D., Isles C., Should diabetes be considered a coronary heart disease risk equivalent? results from 25 years of follow-up in the Renfrew and Paisley survey. Diabetes Care 2005 28 7 1588 1593 2-s2.0-21544465313 10.2337/diacare.28.7.1588 (Pubitemid 40923069)
26. Pajunen P., Taskinen M. R., Nieminen M. S., Syvänne M., Angiographic severity and extent of coronary artery disease in patients with type 1 diabetes mellitus. American Journal of Cardiology 2000 86 10 1080 1085 2-s2.0-0034670084 10.1016/S0002-9149(00)01163-2
27. Moreno P. R., Murcia A. M., Palacios I. F., Leon M. N., Bernardi V. H., Fuster V., Fallon J. T., Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 2000 102 18 2180 2184 2-s2.0-0034739458
28. Burke A. P., Kolodgie F. D., Zieske A., Fowler D. R., Weber D. K., Varghese P. J., Farb A., Virmani R., Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arteriosclerosis, Thrombosis, and Vascular Biology 2004 24 7 1266 1271 2-s2.0-3042818389 10.1161/01.ATV.0000131783.74034.97 (Pubitemid 38880019)
29. de Zeeuw D., Bakker S. J. L., Does the metabolic syndrome add to the diagnosis and treatment of cardiovascular disease? Nature Clinical Practice Cardiovascular Medicine 2008 5 supplement 1 S10 S14 10.1038/ncpcardio1271 (Pubitemid 351935842)
30. Marinou K., Tousoulis D., Antonopoulos A. S., Stefanadi E., Stefanadis C., Obesity and cardiovascular disease: from pathophysiology to risk stratification. International Journal of Cardiology 2010 138 1 3 8 2-s2.0-70749101115 10.1016/j.ijcard.2009.03.135
31. van Gaal L. F., Mertens I. L., de Block C. E., Mechanisms linking obesity with cardiovascular disease. Nature 2006 444 7121 875 880 2-s2.0-33845914986 10.1038/nature05487 (Pubitemid 46028447)
32. Jarvisalo M. J., Raitakari M., Toikka J. O., Putto-Laurila A., Rontu R., Laine S., Lehtimäki T., Rönnemaa T., Viikari J., Raitakari O. T., Endothelial dysfunction and increased arterial intima-media thickness in children with type 1 diabetes. Circulation 2004 109 14 1750 1755 2-s2.0-8144230928 10.1161/01.CIR.0000124725.46165.2C (Pubitemid 38500678)
33. McGill H. C. Jr, McMahan C. A., Zieske A. W., Malcom G. T., Tracy R. E., Strong J. P., Effects of nonlipid risk factors on atherosclerosis in youth with a favorable lipoprotein profile. Circulation 2001 103 11 1546 1550 2-s2.0-0035916878 (Pubitemid 32226263)
34. Järvisalo M. J., Putto-Laurila A., Jartti L., Lehtimäki T., Solakivi T., Rönnemaa T., Raitakari O. T., Carotid artery intima-media thickness in children with type 1 diabetes. Diabetes 2002 51 2 493 498 2-s2.0-0036066930 (Pubitemid 34764808)
35. Lenzen S., The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia 2008 51 2 216 226 2-s2.0-37549029242 10.1007/s00125-007- 0886-7
36. Oehen S., Ohashi P. S., Aichele P., Burki K., Hengartner H., Zinkernagel R. M., Vaccination or tolerance to prevent diabetes. European Journal of Immunology 1992 22 12 3149 3153 2-s2.0-0026457739 10.1002/eji.1830221218
37. Wang J., Takeuchi T., Tanaka S., Kubo S. K., Kayo T., Lu D., Takata K., Koizumi A., Izumi T., A mutation in the insulin 2 gene induces diabetes with severe pancreatic β -cell dysfunction in the Mody mouse. Journal of Clinical Investigation 1999 103 1 27 37 2-s2.0-0032918044 (Pubitemid 29031160)
38. Jun J. Y., Ma Z., Segar L., Spontaneously diabetic Ins2(+/Akita): apoe-deficient mice exhibit exaggerated hypercholesterolemia and atherosclerosis. American Journal of PhysiologyEndocrinology and Metabolism 2011 301 1 E145 E154 10.1152/ajpendo.00034.2011
39. Zhou C., Pridgen B., King N., Xu J., Breslow J. L., Hyperglycemic Ins2AkitaLdlr-/- mice show severely elevated lipid levels and increased atherosclerosis: a model of type 1 diabetic macrovascular disease. Journal of Lipid Research 2011 52 8 1483 1493 10.1194/jlr.M014092
40. Ding H., Hashem M., Wiehler W. B., Lau W., Martin J., Reid J., Triggle C., Endothelial dysfunction in the streptozotocin-induced diabetic apoE-deficient mouse. British Journal of Pharmacology 2005 146 8 1110 1118 2-s2.0-28944444040 10.1038/sj.bjp.0706417 (Pubitemid 41785322)
41. Renard C. B., Kramer F., Johansson F., Lamharzi N., Tannock L. R., von Herrath M. G., Chait A., Bornfeldt K. E., Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. Journal of Clinical Investigation 2004 114 5 659 668 2-s2.0-4944224324 10.1172/JCI200417867 (Pubitemid 39578756)
42. Uusitupa M. I. J., Niskanen L. K., Siitonen O., Voutilainen E., Pyorala K., Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia 1993 36 11 1175 1184 2-s2.0-0027360243 10.1007/BF00401063 (Pubitemid 23314569)
43. Kuusisto J., Mykkanen L., Pyorala K., Laakso M., Non-insulin-dependent diabetes and its metabolic control are important predictors of stroke in elderly subjects. Stroke 1994 25 6 1157 1164 2-s2.0-0028357761 (Pubitemid 24164754)
44. The DCCT Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The diabetes control and complications trial research group. The New England Journal of Medicine 1993 329 14 977 986
45. Nathan D. M., Cleary P. A., Backlund J. Y. C., Genuth S. M., Lachin J. M., Orchard T. J., Raskin P., Zinman B., Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. New England Journal of Medicine 2005 353 25 2643 2653 2-s2.0-29144453326 10.1056/NEJMoa052187 (Pubitemid 41817713)
46. The UKPDS Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK prospective diabetes study (UKPDS) group. The Lancet 1998 352 9131 837 853 10.1016/S0140-6736(98)07019-6 (Pubitemid 28416718)
47. Holman R. R., Paul S. K., Bethel M. A., Matthews D. R., Neil H. A. W., 10-Year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine 2008 359 15 1577 1589 2-s2.0-53749096863 10.1056/NEJMoa0806470
48. Gerstein H. C., Friedewald W. T., Buse J. B., Bigger J. T., Byington R. P., Cushman W. C., Ginsberg H. N., Goff D. C., Grimm R. H., Ismail-Beigi F., Probstfield J. L., Simons-Morton D. G., Effects of intensive glucose lowering in type 2 diabetes. New England Journal of Medicine 2008 358 24 2545 2559 2-s2.0-45149131667 10.1056/NEJMoa0802743 (Pubitemid 351831356)
49. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., Marre M., Cooper M., Glasziou P., Grobbee D., Hamet P., Harrap S., Heller S., Liu L., Mancia G., Mogensen C. E., Pan C., Poulter N., Rodgers A., Williams B., Bompoint S., De Galan B. E., Joshi R., Travert F., Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine 2008 358 24 2560 2572 2-s2.0-45149133036 10.1056/NEJMoa0802987 (Pubitemid 351831357)
50. Duckworth W., Abraira C., Moritz T., Reda D., Emanuele N., Reaven P. D., Zieve F. J., Marks J., Davis S. N., Hayward R., Warren S. R., Goldman S., McCarren M., Vitek M. E., Henderson W. G., Huang G. D., Glucose control and vascular complications in veterans with type 2 diabetes. New England Journal of Medicine 2009 360 2 129 139 2-s2.0-58149389215 10.1056/NEJMoa0808431
51. Galley H. F., Webster N. R., Physiology of the endothelium. British Journal of Anaesthesia 2004 93 1 105 113 2-s2.0-3242761489 10.1093/bja/aeh163 (Pubitemid 38967432)
52. Pober J. S., Sessa W. C., Evolving functions of endothelial cells in inflammation. Nature Reviews Immunology 2007 7 10 803 815 2-s2.0-34748914299 10.1038/nri2171 (Pubitemid 47480307)
53. Orr A. W., Sanders J. M., Bevard M., Coleman E., Sarembock I. J., Schwartz M. A., The subendothelial extracellular matrix modulates NF- κ B activation by flow: a potential role in atherosclerosis. Journal of Cell Biology 2005 169 1 191 202 2-s2.0-17644383381 10.1083/jcb.200410073 (Pubitemid 40562925)
54. Orr A. W., Stockton R., Simmers M. B., Sanders J. M., Sarembock I. J., Blackman B. R., Schwartz M. A., Matrix-specific p21-activated kinase activation regulates vascular permeability in atherogenesis. Journal of Cell Biology 2007 176 5 719 727 2-s2.0-33847339271 10.1083/jcb.200609008 (Pubitemid 46333985)
55. Ley K., Laudanna C., Cybulsky M. I., Nourshargh S., Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nature Reviews Immunology 2007 7 9 678 689 2-s2.0-34548230927 10.1038/nri2156 (Pubitemid 47327397)
56. Bourdillon M. C., Poston R. N., Covacho C., Chignier E., Bricca G., McGregor J. L., ICAM-1 deficiency reduces atherosclerotic lesions in double-knockout mice (ApoE(-/-)/ICAM-1(-/-)) fed a fat or a chow diet. Arteriosclerosis, Thrombosis, and Vascular Biology 2000 20 12 2630 2635 2-s2.0-0033668713
57. Cybulsky M. I., Iiyama K., Li H., Zhu S., Chen M., Iiyama M., Davis V., Gutierrez-Ramos J. C., Connelly P. W., Milstone D. S., A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. Journal of Clinical Investigation 2001 107 10 1255 1262 2-s2.0-0035010184 (Pubitemid 32494542)
58. Ley K., Huo Y., VCAM-1 is critical in atherosclerosis. Journal of Clinical Investigation 2001 107 10 1209 1210 2-s2.0-0035024867 (Pubitemid 32494533)
59. Gurtner G. C., Davis V., Li H., McCoy M. J., Sharpe A., Cybulsky M. I., Targeted disruption of the murine VCAM1 gene: essential role of VCAM-1 in chorioallantoic fusion and placentation. Genes and Development 1995 9 1 1 14 2-s2.0-0028855419
60. Gu L., Okada Y., Clinton S. K., Gerard C., Sukhova G. K., Libby P., Rollins B. J., Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Molecular Cell 1998 2 2 275 281 2-s2.0-0032134003 (Pubitemid 128373654)
61. Pober J. S., Min W., Endothelial cell dysfunction, injury and death. Handbook of Experimental Pharmacology 2006 176, part 2 135 156 2-s2.0-34547418384
62. Buga G. M., Gold M. E., Fukuto J. M., Ignarro L. J., Shear stress-induced release of nitric oxide from endothelial cells grown on beads. Hypertension 1991 17 2 187 193 2-s2.0-0026032652
63. Amezcua J. L., Dusting G. J., Palmer R. M. J., Moncada S., Acetylcholine induces vasodilatation in the rabbit isolated heart through the release of nitric oxide, the endogenous nitrovasodilator. British Journal of Pharmacology 1988 95 3 830 834 2-s2.0-0023686224 (Pubitemid 18266260)
64. Lahera V., Salom M. G., Fiksen-Olsen M. J., Romero J. C., Mediatory role of endothelium-derived nitric oxide in renal vasodilatory and excretory effects of bradykinin. American Journal of Hypertension 1991 4 3, part 1 260 262 2-s2.0-0025765046
65. Scherrer U., Randin D., Vollenweider P., Vollenweider L., Nicod P., Nitric oxide release accounts for insulin's vascular effects in humans. Journal of Clinical Investigation 1994 94 6 2511 2515 2-s2.0-0028113927 (Pubitemid 24379629)
66. Steinberg H. O., Brechtel G., Johnson A., Fineberg N., Baron A. D., Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. Journal of Clinical Investigation 1994 94 3 1172 1179 2-s2.0-0028030813
67. Chen H., Montagnani M., Funahashi T., Shimomura I., Quon M. J., Adiponectin stimulates production of nitric oxide in vascular endothelial cells. Journal of Biological Chemistry 2003 278 45 45021 45026 2-s2.0-0242581695 10.1074/jbc.M307878200 (Pubitemid 37377262)
68. Xia Y., Tsai A. L., Berka V., Zweier J. L., Superoxide generation from endothelial nitric-oxide synthase: a Ca2+/calmodulin-dependent and tetrahydrobiopterin regulatory process. Journal of Biological Chemistry 1998 273 40 25804 25808 2-s2.0-0032475865 10.1074/jbc.273.40.25804 (Pubitemid 28475808)
69. Antoniades C., Shirodaria C., Leeson P., Antonopoulos A., Warrick N., Van-Assche T., Cunnington C., Tousoulis D., Pillai R., Ratnatunga C., Stefanadis C., Channon K. M., Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis. European Heart Journal 2009 30 9 1142 1150 2-s2.0-65949123566 10.1093/eurheartj/ehp061
70. Dumitrescu C., Biondi R., Xia Y., Cardounel A. J., Druhan L. J., Ambrosio G., Zweier J. L., Myocardial ischemia results in tetrahydrobiopterin (BH4) oxidation with impaired endothelial function ameliorated by BHIN4. Proceedings of the National Academy of Sciences of the United States of America 2007 104 38 15081 15086 2-s2.0-35448929005 10.1073/pnas.0702986104 (Pubitemid 47619596)
71. Chen C. A., Wang T. Y., Varadharaj S., Reyes L. A., Hemann C., Talukder M. A. H., Chen Y. R., Druhan L. J., Zweier J. L., S-glutathionylation uncouples eNOS and regulates its cellular and vascular function. Nature 2010 468 7327 1115 1120 2-s2.0-78650810596 10.1038/nature09599
72. Giacco F., Brownlee M., Oxidative stress and diabetic complications. Circulation Research 2010 107 9 1058 1070 2-s2.0-78349297565 10.1161/CIRCRESAHA.110.223545
73. Fatehi-Hassanabad Z., Chan C. B., Furman B. L., Reactive oxygen species and endothelial function in diabetes. European Journal of Pharmacology 2010 636 13 8 17 2-s2.0-77952675536 10.1016/j.ejphar.2010.03.048
74. Oberprieler N. G., Roberts W., Graham A. M., Homer-Vanniasinkam S., Naseem K. M., cGMP-independent inhibition of integrin α IIb β 3-mediated platelet adhesion and outside-in signalling by nitric oxide. FEBS Letters 2007 581 7 1529 1534 2-s2.0-33947397655 10.1016/j.febslet.2007.02.072 (Pubitemid 46452621)
75. Roberts W., Riba R., Homer-Vanniasinkam S., Farndale R. W., Naseem K. M., Nitric oxide specifically inhibits integrin-mediated platelet adhesion and spreading on collagen. Journal of Thrombosis and Haemostasis 2008 6 12 2175 2185 2-s2.0-56749158772 10.1111/j.1538-7836.2008.03190.x
76. Chigaev A., Smagley Y., Sklar L. A., Nitric oxide/cGMP pathway signaling actively down-regulates α 4 β 1-integrin affinity: an unexpected mechanism for inducing cell de-adhesion. BMC Immunology 2011 12 28 10.1186/1471-2172-12-28
77. Draijer R., Atsma D. E., van der Laarse A., van Hinsbergh V. W. M., cGMP and nitric oxide modulate thrombin-induced endothelial permeability: regulation via different pathways in human aortic and umbilical vein endothelial cells. Circulation Research 1995 76 2 199 208 2-s2.0-0028928892
78. Matsushita K., Morrell C. N., Cambien B., Yang S. X., Yamakuchi M., Bao C., Hara M. R., Quick R. A., Cao W., O'Rourke B., Lowenstein J. M., Pevsner J., Wagner D. D., Lowenstein C. J., Nitric oxide regulates exocytosis by S-nitrosylation of N-ethylmaleimide-sensitive factor. Cell 2003 115 2 139 150 2-s2.0-10744220088 10.1016/S0092-8674(03)00803-1 (Pubitemid 37329578)
79. de Caterina R., Libby P., Peng H. B., Thannickal V. J., Rajavashisth T. B., Gimbrone M., Wee Soo Shin, Liao J. K., Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. Journal of Clinical Investigation 1995 96 1 60 68 2-s2.0-0029159779
80. Khan B. V., Harrison D. G., Olbrych M. T., Alexander R. W., Medford R. M., Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proceedings of the National Academy of Sciences of the United States of America 1996 93 17 9114 9119 2-s2.0-0029786764 10.1073/pnas.93.17.9114 (Pubitemid 26282027)
81. Tai S. C., Robb G. B., Marsden P. A., Endothelial nitric oxide synthase: a new paradigm for gene regulation in the injured blood vessel. Arteriosclerosis, Thrombosis, and Vascular Biology 2004 24 3 405 412 2-s2.0-1542373723 10.1161/01.ATV.0000109171.50229.33 (Pubitemid 38326131)
82. Lefer D. J., Jones S. P., Girod W. G., Baines A., Grisham M. B., Cockrell A. S., Huang P. L., Scalia R., Leukocyte-endothelial cell interactions in nitric oxide synthase- deficient mice. American Journal of PhysiologyHeart and Circulatory Physiology 1999 276 6, part 2 H1943 H1950 2-s2.0-0033000347 (Pubitemid 29323478)
83. Rudic R. D., Shesely E. G., Maeda N., Smithies O., Segal S. S., Sessa W. C., Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. Journal of Clinical Investigation 1998 101 4 731 736 2-s2.0-0032520153 (Pubitemid 28096068)
84. Ozaki M., Kawashima S., Yamashita T., Hirase T., Namiki M., Inoue N., Hirata K. I., Yasui H., Sakurai H., Yoshida Y., Masada M., Yokoyama M., Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apoE-deficient mice. Journal of Clinical Investigation 2002 110 3 331 340 2-s2.0-0036330231 10.1172/JCI200215215 (Pubitemid 34847965)
85. Schmidt T. S., McNeill E., Douglas G., Crabtree M. J., Hale A. B., Khoo J., O'Neill C. A., Cheng A., Channon K. M., Alp N. J., Tetrahydrobiopterin supplementation reduces atherosclerosis and vascular inflammation in apolipoprotein E-knockout mice. Clinical Science 2010 119 3 131 142 2-s2.0-77954942970 10.1042/CS20090559
86. Li L., Chen W., Rezvan A., Jo H., Harrison D. G., Tetrahydrobiopterin deficiency and nitric oxide synthase uncoupling contribute to atherosclerosis induced by disturbed flow. Arteriosclerosis, Thrombosis, and Vascular Biology 2011 31 7 1547 1554 10.1161/ATVBAHA.111.226456
87. Ding Y., Vaziri N. D., Coulson R., Kamanna V. S., Roh D. D., Effects of simulated hyperglycemia, insulin, and glucagon on endothelial nitric oxide synthase expression. American Journal of PhysiologyEndocrinology and Metabolism 2000 279 1 E11 E17 (Pubitemid 30609939)
88. Du X. L., Edelstein D., Dimmeler S., Ju Q., Sui C., Brownlee M., Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. Journal of Clinical Investigation 2001 108 9 1341 1348 2-s2.0-0035180299 10.1172/JCI200111235 (Pubitemid 33107762)
89. Hamuro M., Polan J., Natarajan M., Mohan S., High glucose induced nuclear factor κ B mediated inhibition of endothelial cell migration. Atherosclerosis 2002 162 2 277 287 2-s2.0-0036236272 10.1016/S0021-9150(01) 00719-5 (Pubitemid 34460700)
90. Luppi P., Cifarelli V., Tse H., Piganelli J., Trucco M., Human C-peptide antagonises high glucose-induced endothelial dysfunction through the nuclear factor- κ B pathway. Diabetologia 2008 51 8 1534 1543 2-s2.0-48149103214 10.1007/s00125-008-1032-x
91. Piga R., Naito Y., Kokura S., Handa O., Yoshikawa T., Short-term high glucose exposure induces monocyte-endothelial cells adhesion and transmigration by increasing VCAM-1 and MCP-1 expression in human aortic endothelial cells. Atherosclerosis 2007 193 2 328 334 2-s2.0-34447298871 10.1016/j.atherosclerosis. 2006.09.016 (Pubitemid 47058120)
92. Morigi M., Angioletti S., Imberti B., Donadelli R., Micheletti G., Figliuzzi M., Remuzzi A., Zoja C., Remuzzi G., Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion. Journal of Clinical Investigation 1998 101 9 1905 1915 2-s2.0-0032080628 (Pubitemid 28226110)
93. Manduteanu I., Voinea M., Serban G., Simionescu M., High glucose induces enhanced monocyte adhesion to valvular endothelial cells via a mechanism involving ICAM-1, VCAM-1 and CD18. Endothelium 1999 6 4 315 324 2-s2.0-0032865403 (Pubitemid 29364177)
94. Esposito C., Fasoli G., Plati A., Bellotti N., Conte M. M., Cornacchia F., Foschi A., Mazzullo T., Semeraro L., Dal Canton A., Long-term exposure to high glucose up-regulates VCAM-induced endothelial cell adhesiveness to PBMC. Kidney International 2001 59 5 1842 1849 2-s2.0-0035046283 10.1046/j.1523-1755. 2001.0590051842.x (Pubitemid 32336799)
95. Piconi L., Quagliaro L., da Ros R., Assaloni R., Giugliano D., Esposito K., Szabó C., Ceriello A., Intermittent high glucose enhances ICAM-1, VCAM-1, E-selectin and interleukin-6 expression in human umbilical endothelial cells in culture: the role of poly(ADP-ribose) polymerase. Journal of Thrombosis and Haemostasis 2004 2 8 1453 1459 2-s2.0-13244262637 10.1111/j.1538-7836.2004. 00835.x (Pubitemid 40186145)
96. Kim J. A., Berliner J. A., Natarajan R. D., Nadler J. L., Evidence that glucose increases monocyte binding to human aortic endothelial cells. Diabetes 1994 43 9 1103 1107 2-s2.0-0027935267 (Pubitemid 24265471)
97. El-Osta A., Brasacchio D., Yao D., Pocai A., Jones P. L., Roeder R. G., Cooper M. E., Brownlee M., Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. Journal of Experimental Medicine 2008 205 10 2409 2417 2-s2.0-53349101264 10.1084/jem.20081188
98. Patel R. P., Moellering D., Murphy-Ullrich J., Jo H., Beckman J. S., Darley-Usmar V. M., Cell signaling by reactive nitrogen and oxygen species in atherosclerosis. Free Radical Biology and Medicine 2000 28 12 1780 1794 2-s2.0-0034659143 10.1016/S0891-5849(00)00235-5 (Pubitemid 30628665)
99. Sorescu G. P., Song H., Tressel S. L., Hwang J., Dikalov S., Smith D. A., Boyd N. L., Platt M. O., Lassègue B., Griendling K. K., Jo H., Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress induces monocyte adhesion by stimulating reactive oxygen species production from a Nox1-based NADPH oxidase. Circulation Research 2004 95 8 773 779 2-s2.0-6344283050 10.1161/01.RES.0000145728.22878.45 (Pubitemid 39390579)
100. Orr A. W., Hahn C., Blackman B. R., Schwartz M. A., P21-activated kinase signaling regulates oxidant-dependent NF- κ B activation by flow. Circulation Research 2008 103 6 671 679 2-s2.0-53249142641 10.1161/CIRCRESAHA. 108.182097
101. Han D., Ybanez M. D., Ahmadi S., Yeh K., Kaplowitz N., Redox regulation of tumor necrosis factor signaling. Antioxidants and Redox Signaling 2009 11 9 2245 2263 2-s2.0-68949213938 10.1089/ars.2009.2611
102. Li Q., Engelhardt J. F., Interleukin-1 β induction of NF κ B is partially regulated by H2O2-mediated activation of NF κ B-inducing kinase. Journal of Biological Chemistry 2006 281 3 1495 1505 2-s2.0-33644990327 10.1074/jbc.M511153200
103. Liu J., Yang F., Yang X. -P., Jankowski M., Pagano P. J., NAD(P)H oxidase mediates angiotensin II-induced vascular macrophage infiltration and medial hypertrophy. Arteriosclerosis, Thrombosis, and Vascular Biology 2003 23 5 776 782 10.1161/01.ATV.0000066684.37829.16 (Pubitemid 36569243)
104. Cominacini L., Pasini A. F., Garbin U., Davoli A., Tosetti M. L., Campagnola M., Rigoni A., Pastorino A. M., Lo Cascio V., Sawamura T., Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF- κ B through an increased production of intracellular reactive oxygen species. Journal of Biological Chemistry 2000 275 17 12633 12638 2-s2.0-0034724687 10.1074/jbc.275.17.12633 (Pubitemid 30241412)
105. Brandes R. P., Schroder K., Differential vascular functions of Nox family NADPH oxidases. Current Opinion in Lipidology 2008 19 5 513 518 10.1097/MOL.0b013e32830c91e3
106. Gloire G., Legrand-Poels S., Piette J., NF- κ B activation by reactive oxygen species: fifteen years later. Biochemical Pharmacology 2006 72 11 1493 1505 2-s2.0-33750523632 10.1016/j.bcp.2006.04.011 (Pubitemid 44666727)
107. 2-mediated permeability: role of MAPK and occludin. American Journal of PhysiologyCell Physiology 2000 279 1 C21 C30 2-s2.0-0033868337 (Pubitemid 30616618)
108. Okayama N., Kevil C. G., Correia L., Jourd'Heuil D., Itoh M., Grisham M. B., Alexander J. S., Nitric oxide enhances hydrogen peroxide-mediated endothelial permeability in vitro. American Journal of PhysiologyCell Physiology 1997 273 5, part 1 C1581 C1587 2-s2.0-0030712406
109. Galle J., Hansen-Hagge T., Wanner C., Seibold S., Impact of oxidized low density lipoprotein on vascular cells. Atherosclerosis 2006 185 2 219 226 2-s2.0-33644543347 10.1016/j.atherosclerosis.2005.10.005
110. Landmesser U., Dikalov S., Price S. R., McCann L., Fukai T., Holland S. M., Mitch W. E., Harrison D. G., Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. Journal of Clinical Investigation 2003 111 8 1201 1209 2-s2.0-0037399439 10.1172/JCI200314172 (Pubitemid 36519937)
111. Wolff S. P., Jiang Z. Y., Hunt J. V., Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Radical Biology and Medicine 1991 10 5 339 352 2-s2.0-0025853670 10.1016/0891-5849(91)90040-A (Pubitemid 121003905)
112. Eriksson U. J., Borg L. A. H., Diabetes and embryonic malformations: role of substrate-induced free- oxygen radical production for dysmorphogenesis in cultured rat embryos. Diabetes 1993 42 3 411 419 2-s2.0-0027394254 (Pubitemid 23066517)
113. Cai S., Khoo J., Channon K. M., Augmented BH4 by gene transfer restores nitric oxide synthase function in hyperglycemic human endothelial cells. Cardiovascular Research 2005 65 4 823 831 2-s2.0-13844281183 10.1016/j.cardiores.2004.10.040 (Pubitemid 40249727)
114. Jiang Z. Y., Woollard A. C. S., Wolff S. P., Hydrogen peroxide production during experimental protein glycation. FEBS Letters 1990 268 1 69 71 2-s2.0-0025293777 10.1016/0014-5793(90)80974-N (Pubitemid 20233832)
115. Gelain D. P., Dalmolin R. J. S., Belau V. L., Moreira J. C. F., Klamt F., Castro M. A. A., A systematic review of human antioxidant genes. Frontiers in Bioscience 2009 14 12 4457 4463 10.2741/3541
116. Mandarino L. J., Finlayson J., Hassell J. R., High glucose downregulates glucose transport activity in retinal capillary pericytes but not endothelial cells. Investigative Ophthalmology and Visual Science 1994 35 3 964 972 (Pubitemid 24079827)
117. Zou M. H., Shi C., Cohen R. A., Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. Journal of Clinical Investigation 2002 109 6 817 826 2-s2.0-0036199685 10.1172/JCI200214442 (Pubitemid 34263158)
118. Basta G., Lazzerini G., del Turco S., Ratto G. M., Schmidt A. M., de Caterina R., At least 2 distinct pathways generating reactive oxygen species mediate vascular cell adhesion molecule-1 induction by advanced glycation end products. Arteriosclerosis, Thrombosis, and Vascular Biology 2005 25 7 1401 1407 10.1161/01.ATV.0000167522.48370.5e (Pubitemid 40923359)
119. Nishikawa T., Edelstein D., Du X. L., Yamagishi S. I., Matsumura T., Kaneda Y., Yorek M. A., Beebe D., Oates P. J., Hammes H. P., Glardino I., Brownlee M., Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000 404 6779 787 790 2-s2.0-0034643340 10.1038/35008121 (Pubitemid 30212409)
120. Recchioni R., Marcheselli F., Moroni F., Pieri C., Apoptosis in human aortic endothelial cells induced by hyperglycemic condition involves mitochondrial depolarization and is prevented by N-acetyl-L-cysteine. Metabolism 2002 51 11 1384 1388 2-s2.0-0036835825
121. Tsuneki H., Sekizaki N., Suzuki T., Kobayashi S., Wada T., Okamoto T., Kimura I., Sasaoka T., Coenzyme Q10 prevents high glucose-induced oxidative stress in human umbilical vein endothelial cells. European Journal of Pharmacology 2007 566 13 1 10 2-s2.0-34249008430 10.1016/j.ejphar.2007.03.006 (Pubitemid 46782791)
122. Quagliaro L., Piconi L., Assaloni R., da Ros R., Maier A., Zuodar G., Ceriello A., Intermittent high glucose enhances ICAM-1, VCAM-1 and E-selectin
123. Quagliaro L., Piconi L., Assaloni R., da Ros R., Szabó C., Ceriello A., Primary role of superoxide anion generation in the cascade of events leading to endothelial dysfunction and damage in high glucose treated HUVEC. Nutrition, Metabolism and Cardiovascular Diseases 2007 17 4 257 267 10.1016/j.numecd.2006.01.007 (Pubitemid 46551688)
124. Tsao P. S., Niebauer J., Buitrago R., Lin P. S., Wang B. -Y., Cooke J. P., Chen Y. -D.I., Reaven G. M., Interaction of diabetes and hypertension on determinants of endothelial adhesiveness. Arteriosclerosis, Thrombosis, and Vascular Biology 1998 18 6 947 953 (Pubitemid 28272590)
125. Yang X.-Q., Wang Y.-Y., Chen A. F., Increased superoxide contributes to enhancement of vascular contraction in INS2AKITA diabetic mice, an autosomal dominant mutant model. Clinical and Experimental Pharmacology and Physiology 2008 35 9 1097 1103 10.1111/j.1440-1681.2007.04756.x
126. Cumaoglu A., Ozansoy G., Irat A. M., Aricioglu A., Karasu C., Ari N., Effect of long term, non cholesterol lowering dose of fluvastatin treatment on oxidative stress in brain and peripheral tissues of streptozotocin-diabetic rats. European Journal of Pharmacology 2011 654 1 80 85 10.1016/j.ejphar.2010. 11.035
127. Tesfamariam B., Cohen R. A., Free radicals mediate endothelial cell dysfunction caused by elevated glucose. American Journal of PhysiologyHeart and Circulatory Physiology 1992 263 2, part 2 H321 H326 2-s2.0-0026759488
128. Pieper G. M., Divergent actions of chronic insulin treatment in vivo versus acute treatment ex vivo on diabetic-induced endothelial dysfunction. Life Sciences 1997 60 25 PL371 PL376 2-s2.0-0343581298 10.1016/S0024-3205(97)00292-0 (Pubitemid 27237248)
129. Pieper G. M., Siebeneich W., Oral administration of the antioxidant, N-acetylcysteine, abrogates diabetes-induced endothelial dysfunction. Journal of Cardiovascular Pharmacology 1998 32 1 101 105 10.1097/00005344-199807000-00016 (Pubitemid 28304701)
130. Lewis P., Stefanovic N., Pete J., Calkin A. C., Giunti S., Thallas-Bonke V., Jandeleit-Dahm K. A., Allen T. J., Kola I., Cooper M. E., de Haan J. B., Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice. Circulation 2007 115 16 2178 2187 2-s2.0-34247540770 10.1161/CIRCULATIONAHA.106.664250 (Pubitemid 46659070)
131. Brodsky S. V., Gealekman O., Chen J., Zhang F., Togashi N., Crabtree M., Gross S. S., Nasjletti A., Goligorsky M. S., Prevention and reversal of premature endothelial cell senescence and vasculopathy in obesity-induced diabetes by ebselen. Circulation Research 2004 94 3 377 384 2-s2.0-1242275127 10.1161/01.RES.0000111802.09964.EF (Pubitemid 38240730)
132. Chew P., Yuen D. Y. C., Koh P., Stefanovic N., Febbraio M. A., Kola I., Cooper M. E., de Haan J. B., Site-specific antiatherogenic effect of the antioxidant ebselen in the diabetic apolipoprotein E-deficient mouse. Arteriosclerosis, Thrombosis, and Vascular Biology 2009 29 6 823 830 10.1161/ATVBAHA.109.186619
133. Allen C. L., Bayraktutan U., Antioxidants attenuate hyperglycaemia- mediated brain endothelial cell dysfunction and blood-brain barrier hyperpermeability. Diabetes, Obesity and Metabolism 2009 11 5 480 490 2-s2.0-65449158394 10.1111/j.1463-1326.2008.00987.x
134. 2+-nitric oxide signalling pathway. Clinical and Experimental Pharmacology and Physiology 2005 32 9 771 776 10.1111/j.1440-1681.2005.04266.x (Pubitemid 41603157)
135. Drummond G. R., Selemidis S., Griendling K. K., Sobey C. G., Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nature Reviews Drug Discovery 2011 10 6 453 471 10.1038/nrd3403
136. Yusuf S., Dagenais G., Pogue J., Bosch J., Sleight P., Vitamin E supplementation and cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. The New England Journal of Medicine 2000 342 3 154 160 (Pubitemid 30051646)
137. Boaz M., Smetana S., Weinstein T., Matas Z., Gafter U., Iaina A., Knecht A., Weissgarten Y., Brunner D., Fainaru M., Green M. S., Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. The Lancet 2000 356 9237 1213 1218 2-s2.0-0034619027
138. Lonn E. M., Yusuf S., Dzavik V., Doris C. I., Yi Q., Smith S., Moore-Cox A., Bosch J., Riley W. A., Teo K. K., Effects of Ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with Ramipril and vitamin E (SECURE). Circulation 2001 103 7 919 925 2-s2.0-0035916235 (Pubitemid 32183795)
139. Sacco M., Pellegrini F., Roncaglioni M. C., Avanzini F., Tognoni G., Nicolucci A., Primary prevention of cardiovascular events with low dose aspirin and vitamin E in type 2 diabetic patients: results of the primary prevention project (PPP) trial. Diabetes Care 2003 26 12 3264 3272 2-s2.0-0345411332 10.2337/diacare.26.12.3264 (Pubitemid 37466885)
140. Steinhubl S. R., Why have antioxidants failed in clinical trials? American Journal of Cardiology 2008 101 10 14D 19D 2-s2.0-43049180323 10.1016/j.amjcard.2008.02.003
141. Slavina E. S., Madanat A., Pankov A., Diabetes mellitus and atherosclerosis. New England Journal of Medicine 1987 317 13 836 2-s2.0-0023180858 (Pubitemid 17133364)
142. Singh R., Barden A., Mori T., Beilin L., Advanced glycation end-products: a review. Diabetologia 2001 44 2 129 146 2-s2.0-0035135246 10.1007/ s001250051591 (Pubitemid 32156196)
143. John W. G., Gray M. R., Bates D. L., Beacham J. L., Enzyme immunoassaya new technique for estimating hemoglobin A1c. Clinical Chemistry 1993 39 4 663 666 2-s2.0-0027412337 (Pubitemid 23118319)
144. Degenhardt T. P., Thorpe S. R., Baynes J. W., Chemical modification of proteins by methylglyoxal. Cellular and Molecular Biology (Noisy-le-Grand) 1998 44 7 1139 1145 2-s2.0-0001594836
145. Brownlee M., Biochemistry and molecular cell biology of diabetic complications. Nature 2001 414 6865 813 820 2-s2.0-0035856980 10.1038/414813a (Pubitemid 34000785)
146. Thornalley P. J., The glyoxalase system: new developments towards functional characterization of a metabolic pathway fundamental to biological life. Biochemical Journal 1990 269 1 1 11 2-s2.0-0025298551 (Pubitemid 20210831)
147. Wells-Knecht K. J., Zyzak D. V., Litchfield J. E., Thorpe S. R., Baynes J. W., Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. Biochemistry 1995 34 11 3702 3709 2-s2.0-0028951461 10.1021/bi00011a027
148. Wells-Knecht M. C., Thorpe S. R., Baynes J. W., Pathways of formation of glycoxidation products during glycation of collagen. Biochemistry 1995 34 46 15134 15141 2-s2.0-0028826628 10.1021/bi00046a020
149. Thornalley P. J., Protecting the genome: defence against nucleotide glycation and emerging role of glyoxalase I overexpression in multidrug resistance in cancer chemotherapy. Biochemical Society Transactions 2003 31 6 1372 1377 2-s2.0-0348136791 (Pubitemid 38030979)
150. Morcos M., Du X., Pfisterer F., Hutter H., Sayed A. A. R., Thornalley P., Ahmed N., Baynes J., Thorpe S., Kukudov G., Schlotterer A., Bozorgmehr F., El Baki R. A., Stern D., Moehrlen F., Ibrahim Y., Oikonomou D., Hamann A., Becker C., Zeier M., Schwenger V., Miftari N., Humpert P., Hammes H. P., Buechler M., Bierhaus A., Brownlee M., Nawroth P. P., Glyoxalase-1 prevents mitochondrial protein modification and enhances lifespan in caenorhabditis elegans. Aging Cell 2008 7 2 260 269 2-s2.0-40549129694 10.1111/j.1474-9726.2008.00371.x (Pubitemid 351359658)
151. Neeper M., Schmidt A. M., Brett J., Wang F., Pan Y. C. E., Elliston K., Stern D., Shaw A., Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. Journal of Biological Chemistry 1992 267 21 14998 15004 2-s2.0-0026659883
152. Karasu C., Glycoxidative stress and cardiovascular complications in experimentally-induced diabetes: effects of antioxidant treatment. The Open Cardiovascular Medicine Journal 2010 4 240 256 10.2174/1874192401004010240
153. Yan S. D., Schmidt A. M., Anderson G. M., Zhang J., Brett J., Zou Y. S., Pinsky D., Stern D., Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. Journal of Biological Chemistry 1994 269 13 9889 9897 2-s2.0-0028304625 (Pubitemid 24196599)
154. Wautier J. L., Guillausseau P. J., Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes and Metabolism 2001 27 5, part 1 535 542 2-s2.0-0035153678 (Pubitemid 33051702)
155. Schmidt A. M., Hori O., Chen J. X., Crandall J., Zhang J., Cao R., Shi Du Yan, Brett J., Stern D., Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice: a potential mechanism for the accelerated vasculopathy of diabetes. Journal of Clinical Investigation 1995 96 3 1395 1403 2-s2.0-0029088742
156. Higai K., Shimamura A., Matsumoto K., Amadori-modified glycated albumin predominantly induces E-selectin expression on human umbilical vein endothelial cells through NADPH oxidase activation. Clinica Chimica Acta 2006 367 1-2 137 143 2-s2.0-33645818739 10.1016/j.cca.2005.12.008
157. Xu B., Ji Y., Yao K., Cao Y. X., Ferro A., Inhibition of human endothelial cell nitric oxide synthesis by advanced glycation end-products but not glucose: relevance to diabetes. Clinical Science 2005 109 5 439 446 2-s2.0-27844530581 10.1042/CS20050183 (Pubitemid 41640625)
158. Xu B., Chibber R., Ruggerio D., Kohner E., Ritter J., Ferro A., Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB journal 2003 17 10 1289 1291 2-s2.0-0038265440
159. Gao L., Liu W.-H., Luan N.-N., Feng C., Shang T., [Correlation between the expression of high mobility group box 1 and receptor for advanced glycation end products and the onset of pre-eclampsia]. Zhonghua Fu Chan Ke Za Zhi 2008 43 10 746 750
160. Cai W., He J. C., Zhu L., Lu C., Vlassara H., Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor. Proceedings of the National Academy of Sciences of the United States of America 2006 103 37 13801 13806 2-s2.0-33748802532 10.1073/pnas.0600362103 (Pubitemid 44413988)
161. Ishibashi Y., Matsui T., Takeuchi M., Yamagishi S. I., Vardenafil, an inhibitor of phosphodiesterase-5, blocks advanced glycation end product (AGE)-induced up-regulation of monocyte chemoattractant protein-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression via elevation of cGMP. Clinical and Experimental Medicine 2011 11 2 131 135
162. Yao D., Brownlee M., Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes 2010 59 1 249 255 2-s2.0-77449142258 10.2337/db09-0801
163. Sell D. R., Monnir V. M., Structure elucidation of a senescence cross-link from human extracellular matrix. Implication of pentoses in the aging process. Journal of Biological Chemistry 1989 264 36 21597 21602 2-s2.0-0024852380 (Pubitemid 20028722)
164. Bucala R., Tracey K. J., Cerami A., Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. Journal of Clinical Investigation 1991 87 2 432 438 2-s2.0-0026062122
165. Laga M., Cottyn A., van Herreweghe F., Berghe W. V., Haegeman G., van Oostveldt P., Vandekerckhove J., Vancompernolle K., Methylglyoxal suppresses TNF- α -induced NF- κ B activation by inhibiting NF- κ B DNA-binding. Biochemical Pharmacology 2007 74 4 579 589 2-s2.0-34447252547 10.1016/j.bcp.2007.05.026 (Pubitemid 47042011)
166. Bucala R., Vlassara H., Advanced glycosylation end products in diabetic renal and vascular disease. American Journal of Kidney Diseases 1995 26 6 875 888 2-s2.0-0028793924
167. Tanaka H., Dinenno F. A., Monahan K. D., Clevenger C. M., DeSouza C. A., Seals D. R., Aging, habitual exercise, and dynamic arterial compliance. Circulation 2000 102 11 1270 1275 2-s2.0-0034641653
168. Corman B., Duriez M., Poitevin P., Heudes D., Bruneval P., Tedgui A., Levy B. I., Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy. Proceedings of the National Academy of Sciences of the United States of America 1998 95 3 1301 1306 2-s2.0-0032477913 10.1073/pnas.95.3.1301 (Pubitemid 28124953)
169. Goldin A., Beckman J. A., Schmidt A. M., Creager M. A., Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006 114 6 597 605 2-s2.0-33746920337 10.1161/CIRCULATIONAHA.106. 621854 (Pubitemid 44199649)
170. Diez J., Arterial stiffness and extracellular matrix. Advances in Cardiology 2007 44 76 95 2-s2.0-33751097470 10.1159/000096722 (Pubitemid 44763901)
171. Hogan M., Cerami A., Bucala R., Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide. Role in the vascular and renal complications of diabetes mellitus. Journal of Clinical Investigation 1992 90 3 1110 1115 2-s2.0-0026713726
172. Funk S. D., Yurdagul A., Green J. M., Jhaveri K. A., Schwartz M. A., Orr A. W., Matrix-specific protein kinase a signaling regulates p21-activated kinase activation by flow in endothelial cells. Circulation Research 2010 106 8 1394 1403 2-s2.0-77952468065 10.1161/CIRCRESAHA.109.210286
173. Haitoglou C. S., Tsilibary E. C., Brownlee M., Charonis A. S., Altered cellular interactions between endothelial cells and nonenzymatically glucosylated laminin/type IV collagen. Journal of Biological Chemistry 1992 267 18 12404 12407 2-s2.0-0026696647
174. Charonis A. S., Reger L. A., Dege J. E., Kouzi-Koliakos K., Furcht L. T., Wohlhueter R. M., Tsilibary E. C., Laminin alterations after in vitro nonenzymatic glycosylation. Diabetes 1990 39 7 807 814 2-s2.0-0025369394 (Pubitemid 20211429)
175. Yamawaki H., Saito K., Okada M., Hara Y., Methylglyoxal mediates vascular inflammation via JNK and p38 in human endothelial cells. American Journal of PhysiologyCell Physiology 2008 295 6 C1510 C1517 2-s2.0-57349096428 10.1152/ajpcell.00252.2008
176. Tang G., Minemoto Y., Dibling B., Purcell N. H., Li Z., Karin M., Lin A., Inhibition of JNK activation through NF- κ B target genes. Nature 2001 414 6861 313 317 2-s2.0-0035891320 10.1038/35104568 (Pubitemid 33097808)
177. Chan W. H., Wu H. J., Methylglyoxal and high glucose co-treatment induces apoptosis or necrosis in human umbilical vein endothelial cells. Journal of Cellular Biochemistry 2008 103 4 1144 1157 2-s2.0-40349085621 10.1002/jcb.21489 (Pubitemid 351342606)
178. Younis N., Sharma R., Soran H., Charlton-Menys V., Elseweidy M., Durrington P. N., Glycation as an atherogenic modification of LDL. Current Opinion in Lipidology 2008 19 4 378 384 2-s2.0-53149109790 10.1097/MOL. 0b013e328306a057
179. Toma L., Stancu C. S., Botez G. M., Sima A. V., Simionescu M., Irreversibly glycated LDL induce oxidative and inflammatory state in human endothelial cells; added effect of high glucose. Biochemical and Biophysical Research Communications 2009 390 3 877 882 10.1016/j.bbrc.2009.10.066
180. Ma G. M., Halayko A. J., Stelmack G. L., Zhu F., Zhao R., Hillier C. T., Shen G. X., Effects of oxidized and glycated low-density lipoproteins on transcription and secretion of plasminogen activator inhibitor-1 in vascular endothelial cells. Cardiovascular Pathology 2006 15 1 3 10 10.1016/j.carpath. 2005.08.012 (Pubitemid 43088764)
181. Sangle G. V., Chowdhury S. K. R., Xie X., Stelmack G. L., Halayko A. J., Shen G. X., Impairment of mitochondrial respiratory chain activity in aortic endothelial cells induced by glycated low-density lipoprotein. Free Radical Biology and Medicine 2010 48 6 781 790 2-s2.0-76049118700 10.1016/j. freeradbiomed.2009.12.017
182. Dong Y., Wu Y., Wu M., Wang S., Zhang J., Xie Z., Xu J., Song P., Wilson K., Zhao Z., Lyons T., Zou M. H., Activation of protease calpain by oxidized and glycated LDL increases the degradation of endothelial nitric oxide synthase. Journal of Cellular and Molecular Medicine 2009 13 9 2899 2910 2-s2.0-72849111282 10.1111/j.1582-4934.2008.00416.x
183. Watson A. M., Soro-Paavonen A., Sheehy K., Li J., Calkin A. C., Koitka A., Rajan S. N., Brasacchio D., Allen T. J., Cooper M. E., Thomas M. C., Jandeleit-Dahm K. J. A., Delayed intervention with AGE inhibitors attenuates the progression of diabetes-accelerated atherosclerosis in diabetic apolipoprotein E knockout mice. Diabetologia 2011 54 3 681 689
184. Forbes J. M., Yee L. T. L., Thallas V., Lassila M., Candido R., Jandeleit-Dahm K. A., Thomas M. C., Burns W. C., Deemer E. K., Thorpe S. M., Cooper M. E., Allen T. J., Advanced glycation end product-interventions reduce diabetes-accelerated atherosclerosis. Diabetes 2004 53 7 1813 1823 2-s2.0-3042704196 10.2337/diabetes.53.7.1813 (Pubitemid 38857040)
185. Kass D. A., Shapiro E. P., Kawaguchi M., Capriotti A. R., Scuteri A., DeGroof R. C., Lakatta E. G., Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001 104 13 1464 1470 2-s2.0-0035949502 (Pubitemid 32917336)
186. Zieman M. A., A heart that keeps on beating. Behavioral Healthcare 2007 27 9 22 26
187. Brouwers O., Niessen P. M., Ferreira I., Miyata T., Scheffer P. G., Teerlink T., Schrauwen P., Brownlee M., Stehouwer C. D., Schalkwijk C. G., Overexpression of glyoxalase-I reduces hyperglycemiainduced levels of advanced glycation end products and oxidative stress in diabetic rats. Journal of Biological Chemistry 2011 286 2 1374 1380 10.1074/jbc.M110.144097
188. Engelen L., Ferreira I., Brouwers O., Henry R. M. A., Dekker J. M., Nijpels G., Heine R. J., van Greevenbroek M. M. J., van der Kallen C. J. H., Blaak E. E., Feskens E. J. M., Ten Cate H., Stehouwer C. D. A., Schalkwijk C. G., Polymorphisms in glyoxalase 1 gene are not associated with vascular complications: the Hoorn and CoDAM studies. Journal of Hypertension 2009 27 7 1399 1403 2-s2.0-67649732476 10.1097/HJH.0b013e32832af6ba
189. Wu J. C., Li X. H., Peng Y. D., Wang J. B., Tang J. F., Wang Y. F., Association of two glyoxalase 1 gene polymorphisms with nephropathy and retinopathy in type 2 diabetes. Journal of Endocrinological Investigation 2011 34 10 e343 e348
190. Park L., Raman K. G., Lee K. J., Lu Y., Ferran L. J., Choe W. S., Stern D., Schmidt A. M., Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nature Medicine 1998 4 9 1025 1031 2-s2.0-0031717894 10.1038/2012 (Pubitemid 28417334)
191. Bucciarelli L. G., Wendt T., Qu W., Lu Y., Lalla E., Rong L. L., Goova M. T., Moser B., Kislinger T., Lee D. C., Kashyap Y., Stern D. M., Schmidt A. M., RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002 106 22 2827 2835 2-s2.0-0037180531 10.1161/01.CIR.0000039325.03698.36 (Pubitemid 35396983)
192. Harja E., Bu D. X., Hudson B. I., Jong S. C., Shen X., Hallam K., Kalea A. Z., Lu Y., Rosario R. H., Oruganti S., Nikolla Z., Belov D., Lalla E., Ramasamy R., Shi F. Y., Schmidt A. M., Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. Journal of Clinical Investigation 2008 118 1 183 194 2-s2.0-38149078193 10.1172/JCI32703
193. Calcutt N. A., Cooper M. E., Kern T. S., Schmidt A. M., Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nature Reviews Drug Discovery 2009 8 5 417 429 2-s2.0-65449151412 10.1038/nrd2476
194. Gonzalez R. G., Barnett P., Aguayo J., Direct measurement of polyol pathway activity in the ocular lens. Diabetes 1984 33 2 196 199 2-s2.0-0021363571 (Pubitemid 14184708)
195. Morrison A. D., Clements R. S. Jr, Travis S. B., Oski F., Winegrad A. I., Glucose utilization by the polyol pathway in human erythrocytes. Biochemical and Biophysical Research Communications 1970 40 1 199 205
196. Srivastava S. K., Ramana K. V., Bhatnagar A., Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocrine Reviews 2005 26 3 380 392 2-s2.0-18844369302 10.1210/er.2004-0028 (Pubitemid 40691299)
197. Ramasamy R., Goldberg I. J., Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model. Circulation Research 2010 106 9 1449 1458 2-s2.0-77952403264 10.1161/CIRCRESAHA.109.213447
198. Kinoshita J. H., Dvornik D., Kramil M., Gabbay K. H., The effect of an aldose reductase inhibitor on the galactose-exposed rabbit lens. Biochimica et Biophysica Acta 1968 158 3 472 475
199. Varma S. D., Kinoshita J. H., Inhibition of lens aldose reductase by flavonoids: their possible role in the prevention of diabetic cataracts. Biochemical Pharmacology 1976 25 22 2505 2513 2-s2.0-0017200379 10.1016/0006-2952(76)90457-3
200. Varma S. D., Mizuno A., Kinoshita J. H., Diabetic cataracts and flavonoids. Science 1977 195 4274 205 206 2-s2.0-0017337516 (Pubitemid 8039573)
201. Srivastava S. K., Ansari N. H., Prevention of sugar-induced cataractogenesis in rats by butylated hydroxytoluene. Diabetes 1988 37 11 1505 1508 2-s2.0-0023806489
202. Ansari N. H., Srivastava S. K., Allopurinol promotes and butylated hydroxy toluene prevents sugar-induced cataractogenesis. Biochemical and Biophysical Research Communications 1990 168 3 939 943 10.1016/0006-291X(90) 91119-D (Pubitemid 20175970)
203. Ansari N. H., Bhatnagar A., Fulep E., Khanna P., Srivastava S. K., Trolox protects hyperglycemia-induced cataractogenesis in cultured rat lens. Research Communications in Chemical Pathology and Pharmacology 1994 84 1 93 104 (Pubitemid 24127656)
204. Kern T. S., Engerman R. L., Immunohistochemical distribution of aldose reductase. Histochemical Journal 1982 14 3 507 515 2-s2.0-0020316829 (Pubitemid 12059652)
205. Omi H., Okayama N., Shimizu M., Okouchi M., Ito S., Fukutomi T., Itoh M., Participation of high glucose concentrations in neutrophil adhesion and surface expression of adhesion molecules on cultured human endothelial cells: effect of antidiabetic medicines. Journal of Diabetes and its Complications 2002 16 3 201 208 2-s2.0-0036115848 10.1016/S1056-8727(01)00163-5 (Pubitemid 34553327)
206. Ramana K. V., Bhatnagar A., Srivastava S. K., Inhibition of aldose reductase attenuates TNF- α -induced expression of adhesion molecules in endothelial cells. FASEB Journal 2004 18 11 1209 1218 2-s2.0-3442900756 10.1096/fj.04-1650com (Pubitemid 39006883)
207. Srivastava S., Spite M., Trent J. O., West M. B., Ahmed Y., Bhatnagar A., Aldose reductase-catalyzed reduction of aldehyde phospholipids. Journal of Biological Chemistry 2004 279 51 53395 53406 2-s2.0-11244281705 10.1074/jbc.M403416200 (Pubitemid 40063546)
208. Ramana K. V., Dixit B. L., Srivastava S., Balendiran G. K., Srivastava S. K., Bhatnagar A., Selective recognition of glutathiolated aldehydes by aldose reductase. Biochemistry 2000 39 40 12172 12180 2-s2.0-0034633980 10.1021/bi000796e
209. Ramana K. V., Srivastava S. K., Aldose reductase: a novel therapeutic target for inflammatory pathologies. International Journal of Biochemistry and Cell Biology 2010 42 1 17 20 2-s2.0-70749089191 10.1016/j.biocel.2009.09.009
210. Srivastava S., Vladykovskaya E., Barski O. A., Spite M., Kaiserova K., Petrash J. M., Chung S. S., Hunt G., Dawn B., Bhatnagar A., Aldose reductase protects against early atherosclerotic lesion formation in apolipoprotein E-null mice. Circulation Research 2009 105 8 793 802 2-s2.0-70350132637 10.1161/CIRCRESAHA.109.200568
211. Vedantham S., Noh H., Ananthakrishnan R., Human aldose reductase expression accelerates atherosclerosis in diabetic apolipoprotein E-/- mice. Arteriosclerosis, Thrombosis, and Vascular Biology 2011 31 8 1805 1813 10.1161/ATVBAHA.111.226902
212. Vikramadithyan R. K., Hu Y., Noh H. L., Liang C. P., Hallam K., Tall A. R., Ramasamy R., Goldberg I. J., Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice. Journal of Clinical Investigation 2005 115 9 2434 2443 2-s2.0-24644491335 10.1172/JCI24819 (Pubitemid 41266205)
213. Rajapakse A. G., Ming X. F., Carvas J. M., Yang Z., The hexosamine biosynthesis inhibitor azaserine prevents endothelial inflammation and dysfunction under hyperglycemic condition through antioxidant effects. American Journal of PhysiologyHeart and Circulatory Physiology 2009 296 3 H815 H822 2-s2.0-64049093074 10.1152/ajpheart.00756.2008
214. Goldberg H., Whiteside C., Fantus I. G., O-linked β -N-acetylglucosa mine supports p38 MAPK activation by high glucose in glomerular mesangial cells. American Journal of Physiology'Endocrinology and Metabolism 2011 301 4 E713 E726 10.1152/ajpendo.00108.2011
215. Haltiwanger R. S., Blomberg M. A., Hart G. W., Glycosylation of nuclear and cytoplasmic proteins. Purification and characterization of a uridine diphospho-N-acetylglucosamine: polypeptide β -N- acetylglucosaminyltransferase. Journal of Biological Chemistry 1992 267 13 9005 9013 2-s2.0-0026795976
216. Haltiwanger R. S., Holt G. D., Hart G. W., Enzymatic addition of O-GlcNAc to nuclear and cytoplasmic proteins. Identification of a uridine diphospho-N-acetylglucosamine: peptide β -N-acetylglucosaminyltransferase. Journal of Biological Chemistry 1990 265 5 2563 2568
217. Laczy B., Hill B. G., Wang K., Paterson A. J., White C. R., Xing D., Chen Y. F., Darley-Usmar V., Oparil S., Chatham J. C., Protein O-GlcNAcylation: a new signaling paradigm for the cardiovascular system. American Journal of PhysiologyHeart and Circulatory Physiology 2009 296 1 H13 H28 2-s2.0-58149512746 10.1152/ajpheart.01056.2008
218. Laczy B., Marsh S. A., Brocks C. A., Wittmann I., Chatham J. C., Inhibition of O-GlcNAcase in perfused rat hearts by NAG-thiazolines at the time of reperfusion is cardioprotective in an O-GlcNAc-dependent manner. American Journal of PhysiologyHeart and Circulatory Physiology 2010 299 5 H1715 H1727 2-s2.0-78349253110 10.1152/ajpheart.00337.2010
219. Wu T., Zhou H., Jin Z., Bi S., Yang X., Yi D., Liu W., Cardioprotection of salidroside from ischemia/reperfusion injury by increasing N-acetylglucosamine linkage to cellular proteins. European Journal of Pharmacology 2009 613 13 93 99 2-s2.0-65749113176 10.1016/j.ejphar.2009.04.012
220. Ju Y., Hua J., Sakamoto K., Ogawa H., Nagaoka I., Modulation of TNF- α -induced endothelial cell activation by glucosamine, a naturally occurring amino monosaccharide. International Journal of Molecular Medicine 2008 22 6 809 815 2-s2.0-65449154003 10.3892/ijmm00000089
221. Ju Y., Hua J., Sakamoto K., Ogawa H., Nagaoka I., Glucosamine, a naturally occurring amino monosaccharide modulates LL-37-induced endothelial cell activation. International Journal of Molecular Medicine 2008 22 5 657 662 2-s2.0-59149086624 10.3892/ijmm00000069
222. Musicki B., Kramer M. F., Becker R. E., Burnett A. L., Inactivation of phosphorylated endothelial nitric oxide synthase (Ser-1177) by O-GlcNAc in diabetes-associated erectile dysfunction. Proceedings of the National Academy of Sciences of the United States of America 2005 102 33 11870 11875 2-s2.0-23844523172 10.1073/pnas.0502488102 (Pubitemid 41170817)
223. Federici M., Menghini R., Mauriello A., Hribal M. L., Ferrelli F., Lauro D., Sbraccia P., Spagnoli L. G., Sesti G., Lauro R., Insulin-dependent activation of endothelial nitric oxide synthase is impaired by O-linked glycosylation modification of signaling proteins in human coronary endothelial cells. Circulation 2002 106 4 466 472 2-s2.0-0037162342 10.1161/01.CIR. 0000023043.02648.51 (Pubitemid 34803692)
224. Du X. L., Edelstein D., Rossetti L., Fantus I. G., Goldberg H., Ziyadeh F., Wu J., Brownlee M., Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proceedings of the National Academy of Sciences of the United States of America 2000 97 22 12222 12226 2-s2.0-0034710891 10.1073/pnas.97.22.12222
225. Chen Y. Q., Su M., Walia R. R., Hao Q., Covington J. W., Vaughan D. E., Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells. Journal of Biological Chemistry 1998 273 14 8225 8231 2-s2.0-0032478827 10.1074/jbc.273.14.8225 (Pubitemid 28168879)
226. Holt G. D., Hart G. W., The subcellular distribution of terminal N-acetylglucosamine moieties. Localization of a novel protein-saccharidie linkage, O-linked GlcNAc. Journal of Biological Chemistry 1986 261 17 8049 8057 2-s2.0-0023037076 (Pubitemid 17208742)
227. Oates P. J., Aldose reductase, still a compelling target for diabetic neuropathy. Current Drug Targets 2008 9 1 14 36 2-s2.0-38849177363 10.2174/138945008783431781 (Pubitemid 351201678)
228. Srivastava S. K., Yadav U. C. S., Reddy A. B. M., Saxena A., Tammali R., Shoeb M., Ansari N. H., Bhatnagar A., Petrash M. J., Srivastava S., Ramana K. V., Aldose reductase inhibition suppresses oxidative stress-induced inflammatory disorders. Chemico-Biological Interactions 2011 191 13 330 338 10.1016/j.cbi.2011.02.023
229. st century. Current Medicinal Chemistry 2009 16 6 734 752 2-s2.0-65649103414 10.2174/092986709787458362
230. Geraldes P., King G. L., Activation of protein kinase C isoforms and its impact on diabetic complications. Circulation Research 2010 106 8 1319 1331 2-s2.0-77952468064 10.1161/CIRCRESAHA.110.217117
231. Reyland M. E., Protein kinase C isoforms: multi-functional regulators of cell life and death. Frontiers in Bioscience 2009 14 6 2386 2399 10.2741/3385
232. Du X., Matsumura T., Edelstein D., Rossetti L., Zsengellér Z., Szabó C., Brownlee M., Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. Journal of Clinical Investigation 2003 112 7 1049 1057 2-s2.0-0242285699 10.1172/JCI200318127 (Pubitemid 38056320)
233. Thallas-Bonke V., Thorpe S. R., Coughlan M. T., Fukami K., Yap F. Y. T., Sourris K. C., Penfold S. A., Bach L. A., Cooper M. E., Forbes J. M., Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C- α -dependent pathway. Diabetes 2008 57 2 460 469 2-s2.0-40749139536 10.2337/db07-1119
234. 2+/calmodulin- dependent endothelial nitric oxide synthase activity. Circulation research 2001 88 11 E68 E75 10.1161/hh1101.092677 2-s2.0-0035827676
235. Hirata K. I., Kuroda R., Sakoda T., Katayama M., Inoue N., Suematsu M., Kawashima S., Yokoyama M., Inhibition of endothelial nitric oxide synthase activity by protein kinase C. Hypertension 1995 25 2 180 185 2-s2.0-0028798319
236. Jiang X., Yang F., Tan H., Hyperhomocystinemia impairs endothelial function and eNOS activity via PKC activation. Arteriosclerosis, Thrombosis, and Vascular Biology 2005 25 12 2515 2521 (Pubitemid 43732272)
237. Michell B. J., Chen Z. P., Tiganis T., Stapleton D., Katsis F., Power D. A., Sim A. T., Kemp B. E., Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein pinase. Journal of Biological Chemistry 2001 276 21 17625 17628 2-s2.0-0035947574 10.1074/jbc.C100122200
238. Nigro P., Abe J. I., Woo C. H., Satoh K., McClain C., O'Dell M. R., Lee H., Lim J. H., Li J. D., Heo K. S., Fujiwara K., Berk B. C., PKC ζ decreases eNOS protein stability via inhibitory phosphorylation of ERK5. Blood 2010 116 11 1971 1979 2-s2.0-77956942051 10.1182/blood-2010-02-269134
239. Magid R., Davies P. F., Endothelial protein kinase C isoform identity and differential activity of PKC ζ in an athero-susceptible region of porcine aorta. Circulation Research 2005 97 5 443 449 2-s2.0-24744449131 10.1161/01.RES.0000179767.37838.60 (Pubitemid 41298174)
240. Fleming I., Mohamed A., Galle J., Turchanowa L., Brandes R. P., Fisslthaler B., Busse R., Oxidized low-density lipoprotein increases superoxide production by endothelial nitric oxide synthase by inhibiting PKC α Cardiovascular Research 2005 65 4 897 906 (Pubitemid 40249734)
241. Partovian C., Zhuang Z., Moodie K., Lin M., Ouchi N., Sessa W. C., Walsh K., Simons M., PKC α activates eNOS and increases arterial blood flow in vivo. Circulation Research 2005 97 5 482 487 2-s2.0-24744469672 10.1161/01.RES.0000179775.04114.45 (Pubitemid 41298179)
242. Harhaj N. S., Felinski E. A., Wolpert E. B., VEGF activation of protein kinase C stimulates occludin phosphorylation and contributes to endothelial permeability. Investigative Ophthalmology and Visual Science 2006 47 11 5106 5115 (Pubitemid 46586418)
243. Lynch J. J., Ferro T. J., Blumenstock F. A., Brockenauer A. M., Malik A. B., Increased endothelial albumin permeability mediated by protein kinase C activation. Journal of Clinical Investigation 1990 85 6 1991 1998 2-s2.0-0025341631 (Pubitemid 20192977)
244. Williams B., Gallacher B., Patel H., Orme C., Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes 1997 46 9 1497 1503 2-s2.0-0030863502 (Pubitemid 27369089)
245. Park J. Y., Takahara N., Gabriele A., Chou E., Naruse K., Suzuma K., Yamauchi T., Ha S. W., Meier M., Rhodes C. J., King G. L., Induction of endothelin-1 expression by glucose an effect of protein kinase C activation. Diabetes 2000 49 7 1239 1248 2-s2.0-0033949316 (Pubitemid 30439101)
246. Minshall R. D., Vandenbroucke E. E, Holinstat M., Role of protein kinase Czeta in thrombin-induced RhoA activation and inter-endothelial gap formation of human dermal microvessel endothelial cell monolayers. Microvascular Research 2010 80 2 240 249
247. Rahman A., Bando M., Kefer J., Anwar K. N., Malik A. B., Protein kinase C-activated oxidant generation in endothelial cells signals intercellular adhesion molecule-1 gene transcription. Molecular Pharmacology 1999 55 3 575 583 2-s2.0-0033029454 (Pubitemid 29128116)
248. Abe J. I., Role of PKCs and NF- κ B activation in myocardial inflammation: enemy or ally? Journal of Molecular and Cellular Cardiology 2007 43 4 404 408 2-s2.0-34548854496 10.1016/j.yjmcc.2007.07.002 (Pubitemid 47451419)
249. Bolick D. T., Srinivasan S., Whetzel A., 12/15 lipoxygenase mediates monocyte adhesion to aortic endothelium in apolipoprotein E-deficient mice through activation of RhoA and NF- κ B. Arteriosclerosis, Thrombosis, and Vascular Biology 2006 26 6 1260 1266 (Pubitemid 44305368)
250. Kawakami A., Aikawa M., Nitta N., Apolipoprotein CIII-induced THP-1 cell adhesion to endothelial cells involves pertussis toxin-sensitive G protein- and protein kinase C α -mediated nuclear factor- κ B activation. Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 1 219 225 (Pubitemid 46360402)
251. Minami T., Abid R. M., Zhang J., King G., Kodama T., Aird W. C., Thrombin stimulation of vascular adhesion molecule-1 in endothelial cells is mediated by protein kinase C (PKC)- δ -NF- κ B and PKC- ζ -GATA signaling pathways. Journal of Biological Chemistry 2003 278 9 6976 6984 2-s2.0-0037470077 10.1074/jbc.M208974200 (Pubitemid 36800692)
252. Rahman A., Anwar K. N., Uddin S., Xu N., Ye R. D., Platanias L. C., Malik A. B., Protein kinase C- δ regulates thrombin-induced ICAM-1 gene expression in endothelial cells via activation of p38 mitogen-activated protein kinase. Molecular and Cellular Biology 2001 21 16 5554 5565 2-s2.0-0034928727 10.1128/MCB.21.16.5554-5565.2001 (Pubitemid 32702459)
253. Rahman A., Anwar K. N., Malik A. B., Protein kinase C- ζ mediates TNF- α -induced ICAM-1 gene transcription in endothelial cells. American Journal of PhysiologyCell Physiology 2000 279 4 C906 C914 2-s2.0-0033724749
254. Chakravarthy U., Hayes R. G., Stitt A. W., McAuley E., Archer D. B., Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products. Diabetes 1998 47 6 945 952 2-s2.0-0031831261 10.2337/diabetes.47.6.945 (Pubitemid 28255670)
255. Cosentino F., Eto M., de Paolis P., van der Loo B. V., Bachschmid M., Ullrich V., Kouroedov A., Gatti C. D., Joch H., Volpe M., Lüscher T. F., High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells: role of protein kinase C and reactive oxygen species. Circulation 2003 107 7 1017 1023 2-s2.0-0037465359 10.1161/01.CIR.0000051367.92927.07 (Pubitemid 36258726)
256. Inoguchi T., Li P., Umeda F., Yu H. Y., Kakimoto M., Imamura M., Aoki T., Etoh T., Hashimoto T., Naruse M., Sano H., Utsumi H., Nawata H., High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000 49 11 1939 1945 2-s2.0-0033765672
257. Hempel A., Maasch C., Heintze U., Lindschau C., Dietz R., Luft F. C., Haller H., High glucose concentrations increase endothelial cell permeability via activation of protein kinase C α Circulation Research 1997 81 3 363 371 2-s2.0-0030743466 (Pubitemid 27362523)
258. Wolf B. A., Williamson J. R., Easom R. A., Chang K., Sherman W. R., Turk J., Diacylglycerol accumulation and microvascular abnormalities induced by elevated glucose levels. Journal of Clinical Investigation 1991 87 1 31 38 2-s2.0-0026035977
259. Gaudreault N., Perrin R. M., Guo M., Counter regulatory effects of PKC β II and PKC δ on coronary endothelial permeability. Arteriosclerosis, Thrombosis, and Vascular Biology 2008 28 8 1527 1533
260. Pieper G. M., Riaz U. H., Activation of nuclear factor- κ B in cultured endothelial cells by increased glucose concentration: prevention by calphostin C. Journal of Cardiovascular Pharmacology 1997 30 4 528 532 (Pubitemid 27527591)
261. Xu Y., Wang S., Feng L., Zhu Q., Xiang P., He B., Blockade of PKC- β protects HUVEC from advanced glycation end products induced inflammation. International Immunopharmacology 2010 10 12 1552 1559 2-s2.0-78649994498 10.1016/j.intimp.2010.09.006
262. Kouroedov A., Eto M., Joch H., Volpe M., Lüscher T. F., Cosentino F., Selective inhibition of protein kinase C β 2 prevents acute effects of high glucose on vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 2004 110 1 91 96 2-s2.0-3042736838 10.1161/01.CIR.0000133384.38551.A8 (Pubitemid 38880139)
263. Quagliaro L., Piconi L., Assaloni R., Martinelli L., Motz E., Ceriello A., Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 2003 52 11 2795 2804 2-s2.0-0242300561 10.2337/diabetes.52.11.2795 (Pubitemid 37339710)
264. Inoguchi T., Battan R., Handler E., Sportsman J. R., Heath W., King G. L., Preferential elevation of protein kinase C isoform β II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proceedings of the National Academy of Sciences of the United States of America 1992 89 22 11059 11063 2-s2.0-0026489335 10.1073/pnas.89.22.11059
265. Kang N., Alexander G., Park J. K., Maasch C., Buchwalow I., Luft F. C., Haller H., Differential expression of protein kinase C isoforms in streptozotocin- induced diabetic rats. Kidney International 1999 56 5 1737 1750 2-s2.0-0032704786 10.1046/j.1523-1755.1999.00725.x (Pubitemid 29518174)
266. Shiba T., Inoguchi T., Sportsman J. R., Heath W. F., Bursell S., King G. L., Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. American Journal of Physiology 1993 265 5, part 1 E783 E793 2-s2.0-0027139058
267. das Evcimen N., King G. L., The role of protein kinase C activation and the vascular complications of diabetes. Pharmacological Research 2007 55 6 498 510 2-s2.0-34250702110 10.1016/j.phrs.2007.04.016 (Pubitemid 46962309)
268. Booth G., Stalker T. J., Lefer A. M., Scalia R., Mechanisms of amelioration of glucose-induced endothelial dysfunction following inhibition of protein kinase C in vivo. Diabetes 2002 51 5 1556 1564 2-s2.0-0036316767 (Pubitemid 34826625)
269. Harja E., Jong S. C., Lu Y., Leitges M., Yu S. Z., Schmidt A. M., Yan S. F., Mice deficient in PKC β and apolipoprotein E display decreased atherosclerosis. FASEB Journal 2009 23 4 1081 1091 2-s2.0-65349083118 10.1096/fj.08-120345
270. Ishii H., Jirousek M. R., Koya D., Takagi C., Xia P., Clermont A., Bursell S. E., Kern T. S., Ballas L. M., Heath W. F., Stramm L. E., Feener E. P., King G. L., Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. Science 1996 272 5262 728 731 2-s2.0-13344293711 (Pubitemid 26000279)
271. Nangle M. R., Cotter M. A., Cameron N. E., Protein kinase C β inhibition and aorta and corpus cavernosum function in streptozotocin-diabetic mice. European Journal of Pharmacology 2003 475 13 99 106 2-s2.0-0042882849 10.1016/S0014-2999(03)02113-7 (Pubitemid 37088012)
272. Beckman J. A., Goldfine A. B., Gordon M. B., Garrett L. A., Creager M. A., Inhibition of protein kinase C β prevents impaired endothelium- dependent vasodilation caused by hyperglycemia in humans. Circulation Research 2002 90 1 107 111 2-s2.0-0037059549 10.1161/hh0102.102359 (Pubitemid 34074616)
273. Mehta N. N., Sheetz M., Price K., Comiskey L., Amrutia S., Iqbal N., Mohler E. R., Reilly M. P., Selective PKC β inhibition with ruboxistaurin and endothelial function in type-2 diabetes mellitus. Cardiovascular Drugs and Therapy 2009 23 1 17 24 2-s2.0-58549113343 10.1007/s10557-008-6144-5